UroGen Pharma to Report Second Quarter 2024 Financial Results on Tuesday, August 13, 2024
05 Agosto 2024 - 7:00AM
Business Wire
Conference Call and Webcast Scheduled for
Tuesday, August 13, 2024, at 10:00 AM ET
UroGen Pharma Ltd. (Nasdaq: URGN), a biotech company dedicated
to developing and commercializing innovative solutions that treat
urothelial and specialty cancers, today announced that it will
report second quarter 2024 financial results on Tuesday, August 13,
2024, prior to the open of the stock market. The announcement will
be followed by a live audio webcast and conference call at 10:00 AM
Eastern Time.
A live public webcast of the earnings conference call can be
accessed on UroGen’s Investor Relations website. Following the live
webcast, a replay will be available on the site for approximately
30 days.
About UroGen Pharma Ltd.
UroGen is a biotech company dedicated to developing and
commercializing innovative solutions that treat urothelial and
specialty cancers because patients deserve better options. UroGen
has developed RTGel® reverse-thermal hydrogel, a proprietary
sustained-release, hydrogel-based platform technology that has the
potential to improve the therapeutic profiles of existing drugs.
UroGen’s sustained release technology is designed to enable longer
exposure of the urinary tract tissue to medications, making local
therapy a potentially more effective treatment option. Our first
product to treat low-grade upper tract urothelial cancer and
investigational treatment UGN-102 (mitomycin) for intravesical
solution for patients with low-grade non-muscle invasive bladder
cancer are designed to ablate tumors by non-surgical means. UroGen
is headquartered in Princeton, NJ with operations in Israel.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20240805414962/en/
INVESTOR CONTACT: Vincent Perrone Senior Director, Investor
Relations vincent.perrone@urogen.com 609-460-3588 ext. 1093
MEDIA CONTACT: Cindy Romano Director, Corporate Communications
cindy.romano@urogen.com 609-460-3583 ext. 1083
UroGen Pharma (NASDAQ:URGN)
Gráfica de Acción Histórica
De Jul 2024 a Ago 2024
UroGen Pharma (NASDAQ:URGN)
Gráfica de Acción Histórica
De Ago 2023 a Ago 2024
